Summary

There is some uncertainty regarding the appropriate treatment strategy for mild stroke and whether or not thrombolytic therapy with tissue plasminogen activator (tPA) is suitable for less severe stroke patients. This article discusses methods for distinguishing stroke mimics from stroke and the ramifications of tPA in stroke mimics.